** Shares of drug developer AnaptysBio ANAB.O up 3.3% at $24.30 premarket
** H.C. Wainwright upgrades rating to "buy" from "neutral"; raises PT to $38 from $22, representing 61.6% upside to stock's last close
** ANAB said late on Tuesday its arthritis drug showed low disease activity, meeting main goal in mid-stage study over six months to treat patients with moderate-to-severe rheumatoid arthritis
** Company said rosnilimab patients showed significant reductions in mean change from baseline on scale commonly used to measure disease progression
** "We currently assume value for rosnilimab for treatment of RA with 50%," H.C. Wainwright says
** Brokerage sees additional indications such as ulcerative colitis for drug and assets in development as upside to PT
** As of last close, stock up 77.6% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.